iBio (IBIO) Accounts Payable: $3.04 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBIO iBio Inc IBIO
26 GF Score
Price $1.40
GF Value $0.05
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is iBio Accounts Payable?

iBio IBIO -4.44% 26 Accounts Payable is $3.04 Mil as of Mar. 2026. GuruFocus rates IBIO with a GF Score™ of 26/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 2 warning signs investors should review.

iBio's Accounts Payable for the quarter that ended in Mar. 2026 was $3.04 Mil.

iBio's quarterly Accounts Payable declined from Sep. 2025 ($2.82 Mil) to Dec. 2025 ($2.65 Mil) but then increased from Dec. 2025 ($2.65 Mil) to Mar. 2026 ($3.04 Mil).

iBio's annual Accounts Payable declined from Jun. 2023 ($1.85 Mil) to Jun. 2024 ($0.36 Mil) but then increased from Jun. 2024 ($0.36 Mil) to Jun. 2025 ($2.19 Mil).

iBio Accounts Payable Historical Data

* Premium members only.

The historical data trend for iBio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iBio Accounts Payable Chart

iBio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.25 4.26 1.85 0.36 2.19

iBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 2.19 2.82 2.65 3.04
IBIO
26GF Score
iBio Inc IBIO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iBio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.04 Mil mean?
iBio (IBIO) has a Accounts Payable of $3.04 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on iBio and its competitors.
Is iBio's Accounts Payable too high?
iBio's current Accounts Payable is $3.04 Mil. Overall, iBio has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iBio's Accounts Payable compare to ANVS and ATRA?
iBio's Accounts Payable of $3.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on iBio and its competitors. iBio's current Accounts Payable is $3.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iBio stock overvalued right now?
Based on GuruFocus' analysis, iBio (IBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $1.40 — trading 2700% above its estimated fair value. The current Accounts Payable is $3.04 Mil. iBio's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For iBio (IBIO), the current Accounts Payable is $3.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iBio (IBIO) Overvalued in 2026?

Based on GuruFocus' analysis, iBio stock appears to be overvalued. The current stock price of $1.40 is trading 2700% above its estimated GF Value™ of $0.05. GuruFocus considers iBio to be Significantly Overvalued.

Key valuation signals for IBIO:

  • Accounts Payable: $3.04 Mil
  • GF Value™: $0.05 vs. price of $1.40 (2700% above fair value)
  • GF Score™: 26/100 with 2 warning signs

No single metric tells the full story. See the IBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iBio Business Description

Other Exchanges 0JV0:Germany
Address 11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
26GF Score

Get the complete analysis for IBIO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price
$0.05
GF Value